Platforms
Inoviem provides breakthrough protein technologies for each phase of the drug development process.
One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy
PIMS®
Designed to study molecular interactions and predict therapeutic responses in biomedical research
LIPS
Designed to measure drug-target interactions with high accuracy in native environments, including cultured cells and patient tissues.
Biomarkers discovery
Methodology for the proteomic profiling of human individuals in the context of translational evaluation of biomarkers and clinical development of new drug candidates.
Our expertise in translational pharmacology
Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies, developed in a pathological and physiological environment, that uses human tissue.
About us
Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.
Our mission
Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.
